Table 3.
Non-hematological grade 3 and 4 toxicities according to the Common Toxicity Criteria (CTC)
| IDAC (n = 178) (no./no. available (%)) |
HiDAC (n = 642) (no./no. available (%)) |
p | |
|---|---|---|---|
| Hemorrhage CTC ≥ 3° | 4/177 (2.3) | 21/642 (3.3) | 0.656 |
| Infections CTC ≥ 3° | 78/177 (44.1) | 364/642 (56.7) | 0.004 |
| ALAT/ASAT CTC ≥ 3°, | 6/177 (3.4) | 17/642 (2.6) | 0.786 |
| Bilirubin CTC ≥ 3° | 3/177 (1.7) | 10/642 (1.6) | 1.000 |
| Cardiac CTC ≥ 3° | 5/177 (2.8) | 19/642 (3) | 1.000 |
| Creatinine CTC ≥ 3° | 3/178 (1.7) | 3/642 (0.5) | 0.234 |
| Other AE CTC ≥ 3° | 33/177 (18.6) | 137/642 (21.3) | 0.498 |
| Secondary malignancies | 8/177 (5.0%) | 21/642 (3%) | 0.571 |
HiDAC/IDAC high-dose/intermediate-dose cytarabine; CTC common toxicity criteria; ALAT alanine aminotransferase; ASAT aspartate aminotransferase; AE adverse event